Improving Care & Driving Research

Nov 30 - Dec 3, 2023 - Austin, TX

Poster Abstracts

Displaying 1 - 25 of 86

 Poster TitleView PDF
1A randomized trial to evaluate methods of genetic education and disclosure for GBA and LRRK2 testing in Parkinson’s disease.View PDF
2A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of NLY01 in Early Untreated Parkinson’s DiseaseView PDF
3Abnormal Reflexive Blinks in Male and Female Participants with Parkinson's DiseaseView PDF
4Allele frequency analysis of pharmacogenetic variants of Parkinson’s disease in Latinos: A second-look towards clinical reproducibility of resultsView PDF
5An International multi-centre survey of the 'Vitals' dashboard of Parkinson's disease: Updating the Parkinson's care pathwayView PDF
6Antidepressant Exposure Increases Impulse Control Disorder Risk in Parkinson’s Disease: Insights into Neurobiology, Treatment, and the Connection to Bipolar DisorderView PDF
7Association between total CSF protein levels and severity in Parkinson’s diseaseView PDF
8Beyond Increased Muscle Tone: Co-occurrence of Stiff Person Syndrome and Idiopathic Parkinson’s DiseaseView PDF
9Brainstem Tractography and Machine Learning Reveal Subtypes Linked to Variable REM Sleep Behavior Disorder Severity in Parkinson's DiseaseView PDF
10CAPO study: Classical guitar for reducing Parkinson’s disease OnusView PDF
11Characterizing Hand Function in Parkinson’s disease patients via an Electronic Manual Dexterity TaskView PDF
12Clinical Outcomes of the Automated Selection of the Deep Brain Stimulation Parameters for Parkinson Disease Using Neurophysiology – A Pilot Double-blind, Randomized, Crossover TrialView PDF
13Could STN-DBS facilitate the management of vitamin B6 deficiency associated with high-dose levodopa in people living with Parkinson’s disease?View PDF
14Deep Brain Stimulation Effect on REM Sleep Behavior DisorderView PDF
15Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase)View PDF
16Development and Longitudinal Evaluation of the Parkinson’s Disease-Health Index: A Novel Patient-Reported Outcome MeasureView PDF
17Development of a model to estimate underlying Parkinson's disease progression after initiation of symptomatic therapyView PDF
18Discovery of a highly selective, orally bioavailable, brain-penetrant LRRK2 InhibitorView PDF
19Effects of ATH434, a Clinical Phase Small Molecule Drug Candidate with Moderate Affinity for Iron, in Hemiparkinsonian MacaquesView PDF
20Effects of Deep Brain Stimulation on Psychological Well-Being of CaregiversView PDF
21Effects of short-term cannabidiol with delta-9-tetrahydrocannabinol in Parkinson disease: a randomized, placebo-controlled, double-blind trialView PDF
23Examining respiratory phase patterning in individuals with Parkinson’s Disease: A preliminary studyView PDF
24Functional Characterization of GBA1 Mutations in iPSC-derived Midbrain Dopaminergic NeuronsView PDF
25Genetic testing and counseling for Parkinson's disease: a qualitative study of neurologist and genetic counselor experiencesView PDF
26Identification of candidate Parkinson’s disease predisposition genes in multi-generational high-risk pedigreesView PDF
 Poster TitleView PDF